Hebe Agustina Mena, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acids | 2 | 2018 | 125 | 1.030 |
Why?
|
| Neovascularization, Physiologic | 4 | 2019 | 1349 | 0.920 |
Why?
|
| Ceramides | 1 | 2019 | 201 | 0.600 |
Why?
|
| Culture Media | 1 | 2014 | 897 | 0.400 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 1119 | 0.390 |
Why?
|
| Regeneration | 1 | 2019 | 1511 | 0.350 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 1533 | 0.350 |
Why?
|
| Atherosclerosis | 2 | 2024 | 3408 | 0.330 |
Why?
|
| Apoptosis | 5 | 2023 | 9486 | 0.290 |
Why?
|
| Adipose Tissue, Brown | 2 | 2024 | 764 | 0.290 |
Why?
|
| Glucose | 1 | 2018 | 4346 | 0.260 |
Why?
|
| Arginase | 1 | 2024 | 80 | 0.220 |
Why?
|
| Macrophages | 4 | 2024 | 5769 | 0.220 |
Why?
|
| Retinoblastoma | 2 | 2016 | 317 | 0.210 |
Why?
|
| Acetanilides | 1 | 2024 | 169 | 0.210 |
Why?
|
| Docosahexaenoic Acids | 3 | 2024 | 908 | 0.210 |
Why?
|
| Endothelial Cells | 2 | 2018 | 3548 | 0.200 |
Why?
|
| Mice, Nude | 3 | 2018 | 3615 | 0.190 |
Why?
|
| Stem Cells | 1 | 2014 | 3522 | 0.190 |
Why?
|
| Cold Temperature | 1 | 2024 | 785 | 0.180 |
Why?
|
| Cell Proliferation | 5 | 2019 | 10445 | 0.170 |
Why?
|
| Ischemia | 2 | 2019 | 1882 | 0.150 |
Why?
|
| Technology, Pharmaceutical | 1 | 2018 | 84 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2023 | 790 | 0.140 |
Why?
|
| Thiazoles | 1 | 2024 | 1517 | 0.140 |
Why?
|
| Cell Differentiation | 4 | 2019 | 11528 | 0.140 |
Why?
|
| Mice | 10 | 2024 | 81525 | 0.140 |
Why?
|
| Monocytes | 2 | 2023 | 2570 | 0.130 |
Why?
|
| Inflammation | 5 | 2024 | 10773 | 0.130 |
Why?
|
| Cell Polarity | 1 | 2019 | 637 | 0.130 |
Why?
|
| Phagocytosis | 1 | 2021 | 1528 | 0.130 |
Why?
|
| Junin virus | 1 | 2015 | 13 | 0.130 |
Why?
|
| Morphogenesis | 1 | 2019 | 741 | 0.130 |
Why?
|
| Platelet-Rich Plasma | 1 | 2018 | 178 | 0.120 |
Why?
|
| Digoxin | 1 | 2015 | 246 | 0.120 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 560 | 0.110 |
Why?
|
| Retinal Neoplasms | 1 | 2015 | 146 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2023 | 2911 | 0.110 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2017 | 587 | 0.110 |
Why?
|
| Animals | 12 | 2024 | 168459 | 0.100 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 658 | 0.100 |
Why?
|
| Chemotaxis | 1 | 2014 | 598 | 0.090 |
Why?
|
| Cell Movement | 2 | 2019 | 5203 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 1229 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2017 | 2919 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 2496 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 18252 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2015 | 2932 | 0.080 |
Why?
|
| Blood Platelets | 1 | 2019 | 2479 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2022 | 3963 | 0.080 |
Why?
|
| Wound Healing | 2 | 2018 | 2805 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 2645 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 2047 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2024 | 1250 | 0.070 |
Why?
|
| Sepsis | 1 | 2019 | 2585 | 0.060 |
Why?
|
| Adrenergic beta-3 Receptor Agonists | 1 | 2024 | 14 | 0.060 |
Why?
|
| Retina | 1 | 2015 | 2659 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14666 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2015 | 2747 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2019 | 18965 | 0.060 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2024 | 224 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2024 | 731 | 0.050 |
Why?
|
| Thermogenesis | 1 | 2024 | 475 | 0.040 |
Why?
|
| Necrosis | 1 | 2024 | 1611 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2019 | 144 | 0.040 |
Why?
|
| Quail | 1 | 2018 | 40 | 0.040 |
Why?
|
| Chorioallantoic Membrane | 1 | 2018 | 50 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2019 | 517 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2019 | 297 | 0.030 |
Why?
|
| Fibrosis | 1 | 2023 | 2049 | 0.030 |
Why?
|
| Humans | 10 | 2024 | 761504 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2024 | 1902 | 0.030 |
Why?
|
| Collagen | 1 | 2023 | 2638 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2015 | 385 | 0.030 |
Why?
|
| Phenotype | 2 | 2023 | 16591 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13639 | 0.030 |
Why?
|
| Electroretinography | 1 | 2015 | 525 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 22169 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 1935 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2019 | 768 | 0.030 |
Why?
|
| Cytokines | 2 | 2019 | 7396 | 0.030 |
Why?
|
| Cell Communication | 1 | 2019 | 1657 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 2206 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2017 | 1509 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 1886 | 0.020 |
Why?
|
| Male | 3 | 2019 | 360804 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 1809 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 16981 | 0.020 |
Why?
|
| Rabbits | 1 | 2015 | 4772 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10090 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5791 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 5869 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 3712 | 0.010 |
Why?
|
| Aging | 1 | 2023 | 8708 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10766 | 0.010 |
Why?
|
| Obesity | 1 | 2022 | 12947 | 0.010 |
Why?
|
| Middle Aged | 2 | 2024 | 220895 | 0.010 |
Why?
|
| Young Adult | 1 | 2024 | 59243 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39106 | 0.010 |
Why?
|
| Female | 2 | 2024 | 392644 | 0.010 |
Why?
|
| Aged | 1 | 2023 | 169289 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 221177 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 64680 | 0.000 |
Why?
|